This record was last updated January 29, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-01; most recent amendment 2025-01-28.
Status change: Not Yet Recruiting → Recruiting2024-01-29